|
시장보고서
상품코드
1986576
자동 세포 계수 시장 규모, 점유율, 동향 분석 : 제품별, 유형별, 용도별, 최종 용도별, 지역별, 부문별 예측(2026-2033년)Automated Cell Counting Market Size, Share & Trends Analysis Report, By Product (Instruments, Consumables & Accessories), By Type (Flow Cytometers), By Application (Cell Line Development), By End Use, By Region, And Segment Forecasts, 2026 - 2033 |
||||||
자동 세포 계수 시장 요약
세계의 자동 세포 계수 시장 규모는 2025년에 39억 3,000만 달러로 추계되며, 2033년까지 119억 2,000만 달러에 달할 것으로 예상되고 있습니다.
2026-2033년 CAGR 15.4%로 성장할 것으로 예상됩니다. 자동 세포 계수기는 의료 진단, 제약 연구 및 식품 품질 모니터링에서 세포를 계수하고 분석하는 장치입니다.
이들은 유세포분석, 디지털 이미징 등 최신 기술을 이용하여 매우 높은 정확도와 일관성을 가지고 세포를 분석합니다. 만성질환 유병률 증가와 바이오의약품 연구개발(R&D) 확대가 시장 성장을 촉진하는 주요 요인으로 작용하고 있습니다.
세포 분석의 정확성, 효율성, 표준화에 대한 요구 증가
수동 혈구 계수기에서 자동 세포 계수 시스템으로의 전환은 주로 실험실에서 더 높은 정확도, 반복성 및 업무 효율성에 대한 요구로 인해 추진되고 있습니다. 수작업으로 세포를 계수하는 것은 시간이 오래 걸리고, 노동력이 많이 소요되며, 작업자 간 편차가 발생하기 쉬워 대량 처리가 필요한 연구, 임상 진단 및 바이오 제조 환경에서 큰 제약으로 작용하고 있습니다. 자동 세포 계수기는 일관된 정확도로 더 빠른 결과를 제공함으로써 이러한 문제를 해결하고, 데이터 품질 저하 없이 증가하는 검체 처리량을 처리할 수 있도록 도와줍니다.
이러한 수요는 암 연구, 면역학, 줄기세포 연구, 임상 혈액학 등의 분야에서 특히 강하며, 이러한 분야에서는 다운스트림 분석 및 의사결정에 있으며, 신뢰할 수 있는 세포 농도 및 생존율 데이터가 필수적입니다. 연구소가 더 엄격한 일정과 데이터 무결성에 대한 높은 기대에 직면하면서 자동화는 단순한 편의성을 넘어 필수 불가결한 요소가 되어 학술, 임상 및 산업 분야에서 자동 세포 계수 기술의 도입을 직접적으로 가속화하고 있습니다.
바이오의약품 제조 및 세포치료제 확대
바이오의약품 생산 및 세포 기반 치료의 급속한 성장은 자동 세포 계수 시장을 촉진하는 또 다른 주요 요인입니다. 세포 및 유전자 치료, 단클론 항체 및 백신 개발은 상류 및 하류 바이오프로세스 전반에 걸쳐 정확한 세포 모니터링에 크게 의존하고 있습니다. 자동 세포 계수기는 제조 워크플로우에서 빈번하고 표준화된 세포 측정을 가능하게 함으로써 품질관리, 공정 최적화 및 규제 준수에 있으며, 매우 중요한 역할을 합니다.
바이오 제약사들이 연구 단계에서 상업적 생산으로 생산 규모를 확대함에 따라 견고하고 높은 처리량 및 GMP를 준수하는 세포 계수 솔루션에 대한 요구가 증가하고 있습니다. 이러한 추세는 고급 장비에 대한 수요를 증가시킬 뿐만 아니라 일상적인 공정 모니터링에 사용되는 소모품 및 액세서리의 지속적인 매출 창출을 촉진할 것입니다. 전 세계에서 바이오 제조 역량에 대한 투자가 지속적으로 증가함에 따라 자동 세포 계수 시스템은 단순한 실험실 보조 툴이 아닌 핵심 인프라로 인식되고 있습니다.
자주 묻는 질문
목차
제1장 분석 방법·범위
제2장 개요
제3장 시장의 변동 요인·동향·범위
제4장 제품별 사업 분석
제5장 용도별 사업 분석
제6장 최종 용도별 사업 분석
제7장 지역별 사업 분석
제8장 경쟁 구도
KSA 26.04.28Automated Cell Counting Market Summary
The global automated cell counting market size was estimated at USD 3.93 billion in 2025 and is expected to reach USD 11.92 billion by 2033, growing at a CAGR of 15.4% from 2026 to 2033. Automated cell counters are instruments that count and analyze cells in medical diagnostics, pharmaceutical research, and food quality monitoring.
They use modern techniques such as flow cytometry & digital imaging to analyze cells with great precision and consistency. The increased prevalence of chronic diseases, as well as the expansion of biopharma R&D, are major factors driving market growth.
Growing Demand for Accuracy, Efficiency, and Standardization in Cell Analysis
The shift from manual hemocytometers to automated cell counting systems is primarily driven by the need for higher accuracy, reproducibility, and operational efficiency in laboratories. Manual cell counting is time-consuming, labor-intensive, and prone to inter-operator variability, which becomes a significant limitation in high-volume research, clinical diagnostics, and biomanufacturing environments. Automated cell counters address these challenges by delivering faster results with consistent precision, enabling laboratories to meet increasing sample workloads without compromising data quality.
This demand is particularly strong in applications such as cancer research, immunology, stem-cell studies, and clinical hematology, where reliable cell concentration and viability data are critical for downstream analysis and decision-making. As laboratories face tighter timelines and higher expectations for data integrity, automation has become less of a convenience and more of a necessity, directly accelerating adoption of automated cell counting technologies across academic, clinical, and industrial settings.
Expansion of Biopharmaceutical Manufacturing and Cell-Based Therapies
Rapid growth in biopharmaceutical production and cell-based therapies is another major driver fueling the automated cell counting market. Cell and gene therapies, monoclonal antibodies, and vaccine development rely heavily on precise cell monitoring throughout upstream and downstream bioprocessing. Automated cell counters play a vital role in quality control, process optimization, and regulatory compliance by enabling frequent, standardized cell measurements during manufacturing workflows.
As biopharma companies scale production from research to commercial manufacturing, the need for robust, high-throughput, and GMP-compatible cell counting solutions intensifies. This trend not only boosts demand for advanced instruments but also drives recurring revenue from consumables and accessories used in routine process monitoring. With global investments in biomanufacturing capacity continuing to rise, automated cell counting systems are increasingly viewed as core infrastructure rather than auxiliary lab tools.
Global Automated Cell Counting Market Report Segmentation
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, grand view research has segmented the global automated cell counting market report based on product, application, end use, and region:
- Product Outlook (Revenue, USD Million, 2021 - 2033)
- Instruments
- Flow Cytometers
- Image-based Cell Counters
- Electrical Impendence Coulter Counters
- Consumables & Accessories
- Application Outlook (Revenue, USD Million, 2021 - 2033)
- Blood Analysis
- Stem Cell Research
- Cell Line development
- Biologics Production
- Cell & Gene Therapy
- Others
- End Use Channel Outlook (Revenue, USD Million, 2021 - 2033)
- Pharmaceutical & Biotechnology Companies
- Hospitals & Diagnostic laboratories
- Research & Academic Institutes
- Others
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation and Scope
- 1.2. Market Definitions
- 1.2.1. Product Segment
- 1.2.2. Application Segment
- 1.2.3. End-user Segment
- 1.3. Information analysis
- 1.4. Market formulation & data visualization
- 1.5. Data validation & publishing
- 1.6. Information Procurement
- 1.6.1. Primary Research
- 1.7. Information or Data Analysis
- 1.8. Market Formulation & Validation
- 1.9. Market Model
- 1.10. Objectives
- 1.10.1. Objective 1
- 1.10.2. Objective 2
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Snapshot
- 2.3. Competitive Landscape Snapshot
Chapter 3. Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
- 3.2. Market Trends and Outlook
- 3.3. Market Dynamics
- 3.3.1. Increasing prevalence of chronic diseases
- 3.3.2. Technological advancements in cell counting instruments
- 3.3.3. Increasing government funding for cell-based research
- 3.4. Market Restraint Analysis
- 3.4.1. High costs of advanced cell counting systems
- 3.4.2. Low adoption in underdeveloped regions
- 3.5. Business Environment Analysis
- 3.5.1. PESTEL Analysis
- 3.5.2. Porter's Five Forces Analysis
Chapter 4. Product Business Analysis
- 4.1. Segment Dashboard
- 4.2. Global Automated Cell Counting Market: Product Movement Analysis
- 4.3. Instruments
- 4.3.1. Instruments Market, 2021 - 2033 (USD Million)
- 4.3.2. Flow Cytometers
- 4.3.2.1. Flow Cytometers Market, 2021 - 2033 (USD Million)
- 4.3.3. Image-based Cell Counters
- 4.3.3.1. Image-based Cell Counters Market, 2021 - 2033 (USD Million)
- 4.3.4. Electrical Impendence Coulter Counters
- 4.3.4.1. Electrical Impendence Coulter Counters Market, 2021 - 2033 (USD Million)
- 4.4. Consumables & Accessories
- 4.4.1. Consumables & Accessories Market, 2021 - 2033 (USD Million)
Chapter 5. Application Business Analysis
- 5.1. Segment Dashboard
- 5.2. Global Automated Cell Counting Market: Application Movement Analysis
- 5.3. Blood Analysis
- 5.3.1. Blood Analysis Market, 2021 - 2033 (USD Million)
- 5.4. Stem Cell Research
- 5.4.1. Stem Cell Research Market, 2021 - 2033 (USD Million)
- 5.5. Cell Line development
- 5.5.1. Cell Line development Market, 2021 - 2033 (USD Million)
- 5.5.2. Biologics Production
- 5.5.2.1. Biologics Production Market, 2021 - 2033 (USD Million)
- 5.5.3. Cell & Gene Therapy
- 5.5.3.1. Cell & Gene Therapy Market, 2021 - 2033 (USD Million)
- 5.6. Others
- 5.6.1. Others Market, 2021 - 2033 (USD Million)
Chapter 6. End-Use Business Analysis
- 6.1. Segment Dashboard
- 6.2. Global Automated Cell Counting Market: End-Use Movement Analysis
- 6.3. Pharmaceutical & Biotechnology Companies
- 6.3.1. Pharmaceutical & Biotechnology Companies Market, 2021 - 2033 (USD Million)
- 6.4. Hospitals & Diagnostic laboratories
- 6.4.1. Hospitals & Diagnostic laboratories Market, 2021 - 2033 (USD Million)
- 6.5. Research & Academic Institutes
- 6.5.1. Research & Academic Institutes Market, 2021 - 2033 (USD Million)
- 6.6. Others
- 6.6.1. Others Market, 2021 - 2033 (USD Million)
Chapter 7. Regional Business Analysis
- 7.1. Global Automated Cell Counting Market Share By Region, 2025 & 2033
- 7.2. North America
- 7.2.1. North America Automated Cell Counting Market, 2021 - 2033 (USD Million)
- 7.2.2. U.S.
- 7.2.2.1. Key Country Dynamics
- 7.2.2.2. Competitive Scenario
- 7.2.2.3. Regulatory Framework
- 7.2.2.4. U.S. Automated Cell Counting Market, 2021 - 2033 (USD Million)
- 7.2.3. Canada
- 7.2.3.1. Key Country Dynamics
- 7.2.3.2. Competitive Scenario
- 7.2.3.3. Regulatory Framework
- 7.2.3.4. Canada Automated Cell Counting Market, 2021 - 2033 (USD Million)
- 7.2.4. Mexico
- 7.2.4.1. Key Country Dynamics
- 7.2.4.2. Competitive Scenario
- 7.2.4.3. Regulatory Framework
- 7.2.4.4. Mexico Automated Cell Counting Market, 2021 - 2033 (USD Million)
- 7.3. Europe
- 7.3.1. Europe Automated Cell Counting Market, 2021 - 2033 (USD Million)
- 7.3.2. Germany
- 7.3.2.1. Key Country Dynamics
- 7.3.2.2. Competitive Scenario
- 7.3.2.3. Regulatory Framework
- 7.3.2.4. Germany Automated Cell Counting Market, 2021 - 2033 (USD Million)
- 7.3.3. UK
- 7.3.3.1. Key Country Dynamics
- 7.3.3.2. Competitive Scenario
- 7.3.3.3. Regulatory Framework
- 7.3.3.4. UK Automated Cell Counting Market, 2021 - 2033 (USD Million)
- 7.3.4. France
- 7.3.4.1. Key Country Dynamics
- 7.3.4.2. Competitive Scenario
- 7.3.4.3. Regulatory Framework
- 7.3.4.4. France Automated Cell Counting Market, 2021 - 2033 (USD Million)
- 7.3.5. Italy
- 7.3.5.1. Key Country Dynamics
- 7.3.5.2. Competitive Scenario
- 7.3.5.3. Regulatory Framework
- 7.3.5.4. Italy Automated Cell Counting Market, 2021 - 2033 (USD Million)
- 7.3.6. Spain
- 7.3.6.1. Key Country Dynamics
- 7.3.6.2. Competitive Scenario
- 7.3.6.3. Regulatory Framework
- 7.3.6.4. Spain Automated Cell Counting Market, 2021 - 2033 (USD Million)
- 7.3.7. Denmark
- 7.3.7.1. Key Country Dynamics
- 7.3.7.2. Competitive Scenario
- 7.3.7.3. Regulatory Framework
- 7.3.7.4. Denmark Automated Cell Counting Market, 2021 - 2033 (USD Million)
- 7.3.8. Sweden
- 7.3.8.1. Key Country Dynamics
- 7.3.8.2. Competitive Scenario
- 7.3.8.3. Regulatory Framework
- 7.3.8.4. Sweden Automated Cell Counting Market, 2021 - 2033 (USD Million)
- 7.3.9. Norway
- 7.3.9.1. Key Country Dynamics
- 7.3.9.2. Competitive Scenario
- 7.3.9.3. Regulatory Framework
- 7.3.9.4. Norway Automated Cell Counting Market, 2021 - 2033 (USD Million)
- 7.4. Asia Pacific
- 7.4.1. Asia Pacific Automated Cell Counting Market, 2021 - 2033 (USD Million)
- 7.4.2. Japan
- 7.4.2.1. Key Country Dynamics
- 7.4.2.2. Competitive Scenario
- 7.4.2.3. Regulatory Framework
- 7.4.2.4. Japan Automated Cell Counting Market, 2021 - 2033 (USD Million)
- 7.4.3. China
- 7.4.3.1. Key Country Dynamics
- 7.4.3.2. Competitive Scenario
- 7.4.3.3. Regulatory Framework
- 7.4.3.4. China Automated Cell Counting Market, 2021 - 2033 (USD Million)
- 7.4.4. India
- 7.4.4.1. Key Country Dynamics
- 7.4.4.2. Competitive Scenario
- 7.4.4.3. Regulatory Framework
- 7.4.4.4. India Automated Cell Counting Market, 2021 - 2033 (USD Million)
- 7.4.5. South Korea
- 7.4.5.1. Key Country Dynamics
- 7.4.5.2. Competitive Scenario
- 7.4.5.3. Regulatory Framework
- 7.4.5.4. South Korea Automated Cell Counting Market, 2021 - 2033 (USD Million)
- 7.4.6. Australia
- 7.4.6.1. Key Country Dynamics
- 7.4.6.2. Competitive Scenario
- 7.4.6.3. Regulatory Framework
- 7.4.6.4. Australia Automated Cell Counting Market, 2021 - 2033 (USD Million)
- 7.4.7. Thailand
- 7.4.7.1. Key Country Dynamics
- 7.4.7.2. Competitive Scenario
- 7.4.7.3. Regulatory Framework
- 7.4.7.4. Thailand Automated Cell Counting Market, 2021 - 2033 (USD Million)
- 7.5. Latin America
- 7.5.1. Latin America Automated Cell Counting Market, 2021 - 2033 (USD Million)
- 7.5.2. Brazil
- 7.5.2.1. Key Country Dynamics
- 7.5.2.2. Competitive Scenario
- 7.5.2.3. Regulatory Framework
- 7.5.2.4. Brazil Automated Cell Counting Market, 2021 - 2033 (USD Million)
- 7.5.3. Argentina
- 7.5.3.1. Key Country Dynamics
- 7.5.3.2. Competitive Scenario
- 7.5.3.3. Regulatory Framework
- 7.5.3.4. Argentina Automated Cell Counting Market, 2021 - 2033 (USD Million)
- 7.6. MEA
- 7.6.1. MEA Automated Cell Counting Market, 2021 - 2033 (USD Million)
- 7.6.2. South Africa
- 7.6.2.1. Key Country Dynamics
- 7.6.2.2. Competitive Scenario
- 7.6.2.3. Regulatory Framework
- 7.6.2.4. South Africa Automated Cell Counting Market, 2021 - 2033 (USD Million)
- 7.6.3. Saudi Arabia
- 7.6.3.1. Key Country Dynamics
- 7.6.3.2. Competitive Scenario
- 7.6.3.3. Regulatory Framework
- 7.6.3.4. Saudi Arabia Automated Cell Counting Market, 2021 - 2033 (USD Million)
- 7.6.4. UAE
- 7.6.4.1. Key Country Dynamics
- 7.6.4.2. Competitive Scenario
- 7.6.4.3. Regulatory Framework
- 7.6.4.4. UAE Automated Cell Counting Market, 2021 - 2033 (USD Million)
- 7.6.5. Kuwait
- 7.6.5.1. Key Country Dynamics
- 7.6.5.2. Competitive Scenario
- 7.6.5.3. Regulatory Framework
- 7.6.5.4. Kuwait Automated Cell Counting Market, 2021 - 2033 (USD Million)
Chapter 8. Competitive Landscape
- 8.1. Company Categorization
- 8.2. Strategy Mapping
- 8.3. Company Market Position Analysis, 2025
- 8.4. Company Profiles/Listing
- 8.4.1. Thermo Fisher Scientific Inc.
- 8.4.1.1. Overview
- 8.4.1.2. Financial Performance
- 8.4.1.3. Product Benchmarking
- 8.4.1.4. Strategic Initiatives
- 8.4.2. Countstar, Inc.
- 8.4.2.1. Overview
- 8.4.2.2. Product Benchmarking
- 8.4.2.3. Strategic Initiatives
- 8.4.3. Bio-Rad Laboratories, Inc.
- 8.4.3.1. Overview
- 8.4.3.2. Financial Performance
- 8.4.3.3. Product Benchmarking
- 8.4.3.4. Strategic Initiatives
- 8.4.4. F. Hoffmann-La Roche Ltd
- 8.4.4.1. Overview
- 8.4.4.2. Financial Performance
- 8.4.4.3. Product Benchmarking
- 8.4.4.4. Strategic Initiatives
- 8.4.5. Chemometec A/S
- 8.4.5.1. Overview
- 8.4.5.2. Product Benchmarking
- 8.4.5.3. Strategic Initiatives
- 8.4.6. Danaher
- 8.4.6.1. Overview
- 8.4.6.2. Financial Performance
- 8.4.6.3. Product Benchmarking
- 8.4.6.4. Strategic Initiatives
- 8.4.7. Olympus Corporation
- 8.4.7.1. Overview
- 8.4.7.2. Financial Performance
- 8.4.7.3. Product Benchmarking
- 8.4.7.4. Strategic Initiatives
- 8.4.8. Merck KGaA
- 8.4.8.1. Overview
- 8.4.8.2. Financial Performance
- 8.4.8.3. Product Benchmarking
- 8.4.8.4. Strategic Initiatives
- 8.4.9. Sysmex Corporation
- 8.4.9.1. Overview
- 8.4.9.2. Financial Performance
- 8.4.9.3. Product Benchmarking
- 8.4.9.4. Strategic Initiatives
- 8.4.10. Agilent Technologies, Inc.
- 8.4.10.1. Overview
- 8.4.10.2. Financial Performance
- 8.4.10.3. Product Benchmarking
- 8.4.10.4. Strategic Initiatives
- 8.4.11. Abbott
- 8.4.11.1. Overview
- 8.4.11.2. Financial Performance
- 8.4.11.3. Product Benchmarking
- 8.4.11.4. Strategic Initiatives
- 8.4.1. Thermo Fisher Scientific Inc.
